HEARTS Trial for Thoracic Cancers

Conditions

• Esophageal Cancer Stage I-III
• Esophagogastric Cancer Stage I-III
• Non-Small Cell Lung Cancer (Stage III)
• Other Cancers in the Thoracic Region
• Thymoma and Thymic Carcinoma Stage II-III

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• MRgART — RADIATION
  Magnetic Resonance-guided Adaptive Radiation Therapy (MRgART) is a form of MRgRT that incorporates daily adaptive planning, or making a new treatment plan each treatment, and real-time imaging during treatment delivery.
• LINAC — RADIATION
  Daily 3D x-ray scans will be obtained for radiation delivery to confirm tumor and organ at risk placement.

Study Details

The goal of this clinical trial is to compare a new way of using magnetic resonance-guided adaptive radiation therapy (MRgART) to the standard of care linear accelerator (LINAC) radiation treatment in people with cancer in the thoracic region near the heart. The main question it aims to answer is whether MRgART affects the heart differently than LINAC. Participants will: * Receive radiation therapy * Undergo MRIs and bloodwork * Complete quality of life questionnaires

Key Dates

Start date

Oct 8, 2025

Status verified

Mar 2026

Primary completion

Mar 31, 2029

Completion

Mar 31, 2029

Study Design

Enrollment

60 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: MRgART radiation therapy
  Participants randomized to this arm will receive magnetic resonance-guided adaptive radiation therapy (MRgART)
• Experimental: LINAC radiation therapy
  Participants randomized to this arm will receive linear accelerator (LINAC) radiation therapy

Primary Outcome Measure

Change in left ventricular ejection fraction (LVEF) [ Time Frame: Pre-treatment, 3 months post-treatment, 6 months post-treatment ]

Central Contacts

• Cancer Connect
  800-622-8922
  [email protected]

Locations (1)

Find similar trials in Madison, WI